Ronald L Hayes

US Patent:

20210347914, Nov 11, 2021

Filed:

Jul 19, 2021

Appl. No.:

17/379739

Inventors:

- San Diego CA, US
Ronald L. HAYES - San Diego CA, US

Assignee:

Banyan Biomarkers, Inc. - San Diego CA

International Classification:

C07K 16/40
A61P 25/00
A61B 5/00
A61B 5/055
A61B 6/03
A61B 6/00
C07K 16/18
G01N 33/68

Abstract:

The invention provides anti-UCH-L1 antibodies and anti-GFAP antibodies and their use in in vitro detection of UCH-L1 and GFAP, respectively, in a sample from an individual, such as an individual known or suspected of having a brain injury or damage, for example, neurological damage such as mild traumatic brain injury. Also provided are methods, systems and kits for diagnosing brain injury or damage, such as neurological damage, in an individual with the aforementioned antibodies as well as compositions comprising the anti-UCH-L1 antibodies and anti-GFAP antibodies.

US Patent:

20200165355, May 28, 2020

Filed:

Oct 27, 2017

Appl. No.:

16/345562

Inventors:

- San Diego CA, US
Ronald L. HAYES - San Diego CA, US

Assignee:

BANYAN BIOMARKERS, INC. - San Diego CA

International Classification:

C07K 16/40
C07K 16/18
G01N 33/68
A61P 25/00
A61B 5/00
A61B 5/055
A61B 6/03
A61B 6/00

Abstract:

The invention provides anti-UCH-L1 antibodies and anti-GFAP antibodies and their use in vitro detection of UCH-L1 and GFAP, respectively, in a sample from an individual, such as an individual known or suspected of having a brain injury or damage, for example, neurological damage such as mild traumatic brain injury. Also provided are methods, systems and kits for diagnosing brain injury or damage, such as neurological damage, in an individual with the aforementioned antibodies as well as compositions comprising the anti-UCH-L1 antibodies and anti-GFAP antibodies.

US Patent:

20190064188, Feb 28, 2019

Filed:

Aug 1, 2018

Appl. No.:

16/052512

Inventors:

- Alachua FL, US
Zhiqun ZHANG - Auburndale MA, US
Ming-Cheng LIU - Plano TX, US
Ronald L. HAYES - Alachua FL, US

Assignee:

Banyan Biomarkers, Inc. - Alachua FL

International Classification:

G01N 33/68
C07K 16/18
G01N 33/53
G01N 33/564
C12Q 1/6883

Abstract:

Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.

US Patent:

20170315136, Nov 2, 2017

Filed:

Dec 17, 2012

Appl. No.:

13/717405

Inventors:

- Alachua FL, US
Zhiqun Zhang - Auburndale MA, US
Ming Cheng LIU - Plano TX, US
Ronald L. HAYES - Alachua FL, US

Assignee:

BANYAN BIOMARKERS, INC. - Alachua FL

International Classification:

G01N 33/68

Abstract:

A robust, quantitative, and reproducible process and assay for diagnosis of a neurological condition in a subject is provided. With measurement of one or more autoantibodies to biomarkers in a biological fluid such as CSF or serum, the extent of neurological damage in a subject with an abnormal neurological condition is determined and subtypes thereof or tissue types subjected to damage are discerned.

US Patent:

20170242041, Aug 24, 2017

Filed:

Dec 27, 2016

Appl. No.:

15/391755

Inventors:

- Alachua FL, US
Zhiqun ZHANG - Auburndale MA, US
Ming-Cheng LIU - Plano TX, US
Ronald L. HAYES - Alachua FL, US
Jitendra Ramanlal DAVE - Gaithersburg MD, US

Assignee:

BANYAN BIOMARKERS, INC. - Alachua FL

International Classification:

G01N 33/68
G01N 33/53
C07K 16/18
G01N 33/564

Abstract:

Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Parkinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.